Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Novo Nordisk

238.45 DKK

+1.12 %

1,009 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

+1.12 %
+0.02 %
-26.69 %
-28.08 %
-31.58 %
-53.46 %
-54.54 %
+12.09 %
+19,052.61 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.06T DKK
Turnover
1.87B DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.3.
2026

General meeting '26

27.3.
2026

Half year dividend

6.5.
2026

Interim report Q1'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Usage growth has been strong in Finland. I’m not surprised, though, as this is the “promised land” of cardiovascular diseases. I suppose this is a general trend at least in developed countries, especially now that Novo offers a pill alternative. For Novo, however, competition is ...
3/17/2026, 9:40 AM
by Ränta på ränta
18
https://yle.fi/a/74-20216290 Quite a short article, with a few interesting highlights below. A study with nearly 100,000 participants over a 13-year follow-up period. The use of diabetes and weight loss medications significantly alleviated patients’ mental health problems in a recent...
3/21/2026, 4:41 PM
by Krispi
14
IS and IL also have stories today. Lihavuuslääkkeiden käyttö räjähti – näin paljon käyttäjiä oli viime vuonna - Ilta-Sanomat
3/17/2026, 9:01 AM
by Koala
11
The article below doesn’t really concern Novo as an investment, but I thought it might still be of interest in this thread. The article tells how GLP-1 drugs developed by Eli Lilly and Novo Nordisk are changing the food markets so much that food giants have to adapt to people’s new...
3/21/2026, 1:34 PM
by Sijoittaja-alokas
10
https://www.bizjournals.com/triangle/news/2026/03/24/novo-nordisk-wegovy-hd-fda-approval.html High-dose Wegovy gets the green light from the FDA. This was old news anyway, and people are pretty tired of owning this stock - but I’ll post it regardless.
3/24/2026, 2:57 PM
9
5 minutes and an Ozempic prescription from a chat doctor, now even in Finland: Yle Uutiset – 17 Mar 26 Mika sai Ozempicia laihtumiseen parissa tunnissa – laihdutusprofessori:... Laihdutuslääkkeitä käytti viime vuonna yli 100 000 suomalaista. MOT:n selvityksen mukaan chattilääkärit...
3/17/2026, 8:30 AM
by Trokari
9
I see it such that Novo is pushing the price of the drug down, causing demand to grow, and the need for a massive increase in production is greater than the capacity they can build on their own. At current prices, weight-loss drugs are a luxury for the wealthy, and the wealthy, educated...
3/9/2026, 4:21 PM
by Kari Kokkonen
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.